BR100 Increased By (0.02%)
BR30 Increased By (0.06%)
KSE100 Decreased By (-0%)
KSE30 Increased By (0.05%)
BECO 5.52 Decreased By ▼ -0.02 (-0.36%)
BML 56.70 Decreased By ▼ -0.39 (-0.68%)
BOP 35.20 Decreased By ▼ -0.01 (-0.03%)
CNERGY 8.15 Decreased By ▼ -0.05 (-0.61%)
DCL 11.61 Decreased By ▼ -0.03 (-0.26%)
FCCL 56.61 Increased By ▲ 0.12 (0.21%)
FCSC 5.38 Increased By ▲ 0.06 (1.13%)
FFL 17.95 Decreased By ▼ -0.11 (-0.61%)
FNEL 1.29 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.09 (-0.8%)
KEL 8.39 Increased By ▲ 0.19 (2.32%)
KOSM 6.63 Decreased By ▼ -0.04 (-0.6%)
MLCF 101.06 Increased By ▲ 0.30 (0.3%)
NBP 202.44 Decreased By ▼ -0.56 (-0.28%)
PACE 11.42 Decreased By ▼ -0.07 (-0.61%)
PAEL 43.32 Increased By ▲ 0.24 (0.56%)
PIAHCLA 27.24 Increased By ▲ 0.24 (0.89%)
PIBTL 17.82 Decreased By ▼ -0.02 (-0.11%)
PPL 244.79 Increased By ▲ 2.16 (0.89%)
PRL 35.71 Decreased By ▼ -0.16 (-0.45%)
PTC 65.45 Decreased By ▼ -0.40 (-0.61%)
SEARL 93.55 Decreased By ▼ -0.03 (-0.03%)
SSGC 32.98 Increased By ▲ 0.75 (2.33%)
TELE 9.04 Decreased By ▼ -0.07 (-0.77%)
THCCL 66.80 Increased By ▲ 0.31 (0.47%)
TPLP 10.85 Decreased By ▼ -0.10 (-0.91%)
TREET 25.48 Decreased By ▼ -0.24 (-0.93%)
TRG 65.90 Decreased By ▼ -0.05 (-0.08%)
WAVES 11.13 Decreased By ▼ -0.03 (-0.27%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
Business & Finance

Novartis in talks on helping make COVID-19 vaccines, tests

  • Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry.
  • We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible.
Published January 28, 2021 Updated January 28, 2021 07:09pm
By

ZURICH: Novartis is talking to other companies about helping to make vaccines and tests for COVID-19, the Swiss drugmaker said on Thursday without providing more details.

"Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry, and leverage our manufacturing capacity and capabilities to contribute to the pandemic effort," it said in response to a query.

"We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible."

Novartis last year agreed to license two of Molecular Partners' antiviral drugs that it hopes to use to treat COVID-19 patients.

Novartis's gene therapy unit AveXis also last year signed a manufacturing agreement to produce a novel genetic COVID-19 vaccine being developed by the US-based Mass General Brigham health care system.

Comments

Comments are closed for this article.